Loading
Latest filing published 09 Mar 2026 for 광동제약, €25k. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
배기룡, listed as chief executive, appears in our data through filings on 광동제약 shares, published by DART (FSS). In total, 2 filings cover trades dated from 26 July 2021 to 27 February 2026.
The open-market record is one-sided, with 2 purchases worth €25k and not one sale. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: 1 purchase and no sales on the market.
The record was last updated on 9 March 2026 with an open-market purchase (€25k) in 광동제약. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.